Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.

Tarhini AA, Kirkwood JM.

Curr Opin Mol Ther. 2007 Oct;9(5):505-14. Review.

PMID:
17932815
2.

Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.

Camacho LH.

Expert Opin Investig Drugs. 2008 Mar;17(3):371-85. doi: 10.1517/13543784.17.3.371 . Review.

PMID:
18321236
3.

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7. Epub 2003 Apr 7.

4.

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J.

Oncologist. 2007 Jul;12(7):873-83. Review.

5.

Tremelimumab.

[No authors listed]

Drugs R D. 2010;10(2):123-32. doi: 10.2165/11584530-000000000-00000. Review.

6.

Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.

Tarhini AA, Kirkwood JM.

Expert Opin Biol Ther. 2008 Oct;8(10):1583-93. doi: 10.1517/14712598.8.10.1583 .

PMID:
18774925
7.

Clinical development of the anti-CTLA-4 antibody tremelimumab.

Ribas A.

Semin Oncol. 2010 Oct;37(5):450-4. doi: 10.1053/j.seminoncol.2010.09.010. Review.

PMID:
21074059
8.

The role of the CTLA4 blockade in the treatment of malignant melanoma.

Cranmer LD, Hersh E.

Cancer Invest. 2007 Oct;25(7):613-31. Review.

PMID:
18027152
9.
10.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).

Ribas A.

Oncologist. 2008;13 Suppl 4:10-5. doi: 10.1634/theoncologist.13-S4-10. Review.

11.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7. Epub 2003 Jun 25.

12.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J.

J Clin Oncol. 2005 Dec 10;23(35):8968-77. Epub 2005 Oct 3.

PMID:
16204013
13.

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J.

J Clin Oncol. 2005 Feb 1;23(4):741-50. Epub 2004 Dec 21.

PMID:
15613700
14.

Future directions in tumor immunotherapy: CTLA4 blockade.

Gulley JL, Dahut WL.

Nat Clin Pract Oncol. 2007 Mar;4(3):136-7. No abstract available.

PMID:
17327854
15.

CTLA-4 blockade: autoimmunity as treatment.

Kapadia D, Fong L.

J Clin Oncol. 2005 Dec 10;23(35):8926-8. Epub 2005 Oct 3. No abstract available.

PMID:
16204008
16.

Treating cancer by targeting the immune system.

Hwu P.

N Engl J Med. 2010 Aug 19;363(8):779-81. doi: 10.1056/NEJMe1006416. No abstract available.

PMID:
20818880
17.

Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.

Theoret MR, Arlen PM, Pazdur M, Dahut WL, Schlom J, Gulley JL.

Clin Genitourin Cancer. 2007 Jun;5(5):347-50. No abstract available.

PMID:
17645835
18.

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A.

Eur J Cancer. 2015 Nov;51(17):2689-97. doi: 10.1016/j.ejca.2015.08.012. Epub 2015 Sep 10.

19.
20.

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB.

J Clin Oncol. 2010 Jul 20;28(21):3485-90. doi: 10.1200/JCO.2010.28.3994. Epub 2010 May 24.

PMID:
20498386

Supplemental Content

Support Center